clinical trial · NCT06089824
Drug Utilisation of Mysimba/Contrave
Obesity
brief summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
started
Sep 1, 2014
primary completion
Oct 1, 2022
completion
Oct 1, 2022
last updated
Oct 18, 2023
official title
Drug Utilisation and Safety Study of Mysimba in Europe and Contrave in the United States
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol